Vandana Abramson
Vanderbilt University/Ingram Cancer Center · Vanderbilt University · Vanderbilt-Ingram Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Vandana Abramson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:42 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05770531 · Circulating Tumor DNA to Guide Changes in Standard of Care ChemotherapyVanderbilt-Ingram Cancer Center · recruiting · Metastatic HER2-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma · principal investigator
- Ph1NCT02672475 · Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast CancerVanderbilt-Ingram Cancer Center · completed · Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative · principal investigator
- Ph1/Ph2NCT02457910 · Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast CancerVanderbilt-Ingram Cancer Center · terminated · Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative · principal investigator
- Ph2NCT01240941 · Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast CancerVanderbilt-Ingram Cancer Center · withdrawn · Metastatic Breast Cancer · principal investigator
- Ph1NCT01240928 · MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast CancerVanderbilt-Ingram Cancer Center · withdrawn · Metastatic Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Improving Outcomes for Patients with Triple-Negative Breast CancerR01CA312128 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · fiscal years 2026 · $400,313 awarded in 2026Same name and institution; not confirmed by an ID
- Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant TherapyU01CA142565 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · fiscal years 2010 to 2018 · $461,172 awarded in 2018Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Leadership Planning and EvaluationP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · fiscal years 2014 to 2026Named on NCT02672475, NCT02457910
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:42 UTC. The ranking covers the 200 most relevant of 41 PubMed records, and a shared surname and initials can bring in a namesake. All 41 on PubMed
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.N Engl J Med · 20201,043 citationsRCR 46.1
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.N Engl J Med · 2019713 citationsRCR 26.7
- 458 citationsRCR 17.8
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.J Clin Oncol · 2017349 citationsRCR 10.7
- Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.Clin Cancer Res · 2012306 citationsRCR 7.0
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.Clin Cancer Res · 2017263 citationsRCR 7.6
- Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.Cancer Discov · 2021222 citationsRCR 10.9
- 205 citationsRCR 14.5
- Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.Breast Cancer Res · 2019186 citationsRCR 6.9
- 182 citationsRCR 16.5